Development License. Subject to the terms and conditions of this Agreement, on a Licensed Product-by-Licensed Product basis, aTyr hereby grants Kyorin a non-transferable (except as provided in Section 14.1), sublicensable (subject to [Sections 3.6 and 7.1.1.3]) exclusive (even as to aTyr and its Affiliates) license under the aTyr Licensed Technology and aTyr’s interest in the New Joint IP in the Kyorin Territory to Develop such Licensed Product in the Field anywhere in the Kyorin Territory; provided, however, that such license grant for Development will be limited in each case solely as and to the extent provided in the approved Kyorin Development Plan for such Licensed Product or as otherwise permitted elsewhere under this Agreement, and in each case, solely for purposes of obtaining Regulatory Approval of such Licensed Product in the Kyorin Territory and Commercialization of such Licensed Product in the Kyorin Territory. Notwithstanding the foregoing exclusive grant, aTyr retains the right under the aTyr Licensed Technology and aTyr’s interest in the New Joint IP, with the right to grant licenses through multiple tiers in accordance with Section 7.1.2.3, which will apply mutatis mutandis, to # Develop each Licensed Product in the Field anywhere in the world solely for obtaining Regulatory Approval of Licensed Products and Commercialization of Licensed Products in the aTyr Territory, and # conduct activities to be conducted by or on behalf of aTyr in the Kyorin Territory under the Global Development Plan and Kyorin Development Plan, as applicable.

Development License. Subject to the terms and conditions of this Agreement, including Section 4.3(a)(i), [[GlycoMimetics:Organization]] hereby grants, and shall cause its Affiliates to grant to, Apollomics, a non-exclusive license under # the [[GlycoMimetics:Organization]] Technology and # the [[GlycoMimetics:Organization]] Development Technology to conduct preclinical research with respect to Licensed Products in the Field in the [[GlycoMimetics:Organization]] Territory for the purpose of developing such Licensed Products for use in the Apollomics Territory.

Development License. Subject to the terms and conditions of this Agreement, Arrowhead hereby grants to Janssen an exclusive (even as to Arrowhead, except to the extent Arrowhead expressly retains or is expressly granted back rights under this Agreement), worldwide license, with the right to sublicense in accordance with [Section 2.1.4], under Arrowhead Intellectual Property, to research and have researched, and to Develop and have Developed Licensed Constructs and Licensed Products, in the Field in the Territory, and to make and Manufacture, have made and Manufactured, use, have used, and import and have imported Licensed Constructs and Licensed Products for such purposes. The license rights granted under this [Section 2.1.2] shall commence, on a Program-by-Program basis, when Arrowhead provides Janssen with a Target Reply accepting a Target, and run throughout the Term hereof, subject to the termination provisions under Article XV.

Development License. Subject to the terms and conditions of this Agreement, Nektar hereby grants, and shall cause its Affiliates to grant, to BMS (and BMS hereby

Development License. Subject to the terms and conditions of this Agreement, BMS hereby grants, and shall cause its Affiliates to grant, to Nektar (and Nektar hereby accepts) a non-exclusive, worldwide, non-transferable (except as provided in [Section 17.12]), royalty-free license (with the right to sublicense solely pursuant to the terms of and subject to the limitations of Section 11.3) under # BMS Asset Patent Rights, # BMS Background Patent Rights, # BMS Technology, and # BMS Regulatory Documentation, in each case in respect of clauses (i)-(iv), solely to use, Develop and have Developed BMS Assets in combination with Nektar Assets and/or Nektar Compounds and Product (as part of a Combined Therapy), whether with or without Third Party Assets, in the Field in the Territory, in each case solely to the extent necessary to discharge Nektar’s obligations and exercise its rights under this Agreement with respect to the conduct of the Collaboration Studies, Independent Studies and the activities described in Section 3.9.

Development and License Agreement. The Development and License Agreement shall be in full force and effect, and the “HSR Clearance Date,” if applicable, and the “Effective Date” under the Development and License Agreement each shall have occurred.

License. Effective on iTeos’s exercise of the Option, [[Adimab:Organization]] hereby grants to iTeos a worldwide, royalty-bearing, non-exclusive, sublicenseable (solely as provided in [Section 3.2(b)(iii)] (Licensees)) license under the # [[Adimab:Organization]] Platform Patents, # [[Adimab:Organization]] Platform Technology, # [[Adimab:Organization]] Platform Technology Improvements and # Program Antibody Patents, if any, which are not assigned to iTeos pursuant to Section 3.2(b)(i) (Assignment), each of (a)-(d) in the Field, to research, develop, have developed, make, have made, use, sell, offer to sell, import and export the Optioned Antibodies and Products during the Term of this Agreement. For clarity, the license to iTeos excludes the right to # discover or optimize antibodies using the [[Adimab:Organization]] Platform Technology or [[Adimab:Organization]] Platform Technology Improvements, or # use Program-Benefited Antibodies or [[Adimab:Organization]] Materials to (aa) screen for other antibodies’ activity vis-a-vis the applicable Target or (bb) design other antibodies (in the case of either (aa) or (bb), other than Program-Benefited Antibodies that will be milestone- and royalty-bearing to [[Adimab:Organization]] under this Agreement).

License. Each Party (the “Trademark Licensor”) grants the other Party and its Affiliates (the “Trademark Licensee”) a non-exclusive license to use Trademark Licensor’s Marks in the exercise of Trademark Licensee’s rights and the performance of Trademark Licensee’s obligations under this Agreement; provided, that Trademark Licensee # does not create a unitary composite mark involving any Mark of Trademark Licensor without the prior written approval of Trademark Licensor and # displays symbols and notices clearly and sufficiently indicating the trademark status and ownership of Trademark Licensor’s Marks in accordance with applicable trademark law and practice and Trademark Licensor’s then current trademark guidelines. The Parties may add, modify

License. Commencing on June 1, 2019 (the “Amenities Commencement Date”), through the Extended Expiration Date, so long as The Alexandria and the Project continue to be owned by affiliates of ARE, Tenant shall have the non-exclusive right to the use of the available Amenities in common with other Users pursuant to the terms of this Section 7. Tenant shall be entitled to 2.5 passes to the fitness center located at The Alexandria per 1,000 rentable square feet of the Premises for use by employees of Tenant employed at the Premises. If any employee of Tenant to whom a fitness center pass has been issued ceases to be an employee of Tenant at the Premises or any employee to whom an access card (which does not include a fitness center pass) has been issued ceases to be an employee of Tenant at the Premises, Tenant shall within a reasonable period following such employee’s change in status collect such employee’s pass or access card, as applicable, and deliver it to Landlord along with written notice of such employee’s change in status.

License. Consultant agrees that if in the course of performing the Services, Consultant incorporates into any Inventions and Materials developed hereunder any invention, improvement, development concept, discovery or other proprietary information owned by Consultant or in which Consultant has an interest, Company is hereby granted and shall have a nonexclusive, royalty-free, fully paid-up, perpetual, irrevocable, worldwide license, with right to sublicense, to reproduce, prepare derivative works of, publicly perform, publicly display in any form or medium, whether now known or later developed, distribute (by any means known or hereafter developed, including without limitation electronic and Internet distribution), make have made, use, sell, offer for sale, and import such item as part of or in connection with such Inventions and Materials.